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Introduction
Nephritis is the most common severe manifestation of
pediatric Systemic Lupus Erythematosus (pSLE) and the
major predictor of poor prognosis. Research for the
detection of novel and accurate biomarkers, predictive of
the nephritis outcome, is globally in progress. Ethnicity
affects the disease outcome but data on purely Caucasian
populations are still limited.
Objectives
The exploration of the role of serum biomarkers, namely
anti-nucleosome antibodies (anti-NCS), anti-C1q antibo-
dies (anti-C1q), anti-glomerular basement membrane anti-
bodies (anti-GBM) and high mobility group box 1 protein
(HMGB1) in pSLE nephritis and the association of their
levels with pSLE nephritis and pSLE disease activity.
Methods
Twenty-four patients (16 female) with pSLE nephritis
(44 serum samples, 22 in active nephritis) and 21 patients
(18 female) with pSLE without nephritis (32 serum sam-
ples, 19 in active pSLE) were enrolled in the study. The
disease control group included 17 patients with nephritis
of other causality (Henoch-Schönlein purpura nephritis,
IgA nephropathy, postinfectious glomerulonephritis,
membranous glomerulonephritis), who provided equal
serum samples. The SLICC renal activity score was applied
for assessing pSLE nephritis disease activity and ECLAM
for global pSLE disease activity. The biomarkers’ levels
were determined by ELISA.
Results
The pSLE nephritis patients had significantly higher
serum levels of anti-NCS [median: 48.89 (IQR: 31.48-
80.81) U/ml versus 12.5 (11.5-27.8) U/ml, p < 0.001],
anti-C1q [22.75 (12.77-56.4) U/ml versus 12.5 (12.5-
12.5) U/ml, p < 0.001], anti-GBM [3.88 (2.25-6.94) U/ml
versus 2.2 (2.2-2.4) U/ml, p = 0.002] and HMGB1 [9.9
(5.7-32.23) ng/ml versus 2.5 (2.5-2.5) ng/ml, p < 0,001],
than the patients with nephritis of other causality.
Serum anti-GBM levels were significantly higher in the
pSLE nephritis patients compared to the pSLE patients
without nephritis [3.88 (2.25-6.94) U/ml versus 2.25
(2.2-2.83) U/ml, p = 0.014], while this was not true for
the rest of the biomarkers. In the pSLE nephritis
patients no correlation was found between serum anti-
GBM levels and pSLE nephritis disease activity. Serum
anti-NCS and anti-C1q levels were positively correlated
with the ECLAM score in the pSLE patients as a whole
(p = 0.002, rho = 0.492 and p = 0.007, rho = 0.461,
respectively).
Conclusion
In this pure Caucasian Northern Greek pSLE population,
high serum anti-GBM levels were found to be associated
with the presence of nephritis, but not with the nephritis
disease activity. Serum anti-GBM, anti-NCS, anti-C1q and
HMGB1 may be used to differentiate patients with pSLE
nephritis from patients with nephritis of other causality.
Furthermore, serum anti-NCS and anti-C1q may be useful
for the estimation of pSLE disease activity.
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